Beyond Air, Inc. (XAIR)
| Market Cap | 231.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -47.37M |
| Shares Out | 29.89M |
| EPS (ttm) | -1.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 170,952 |
| Open | 7.54 |
| Previous Close | 7.44 |
| Day's Range | 7.30 - 7.90 |
| 52-Week Range | 4.79 - 16.41 |
| Beta | -0.25 |
| Analysts | Buy |
| Price Target | 18.97 (+145.4%) |
| Earnings Date | Nov 9, 2022 |
About XAIR
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteri... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for XAIR stock is "Buy." The 12-month stock price forecast is 18.97, which is an increase of 145.41% from the latest price.
News
Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of Hig...
GARDEN CITY, N.Y., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of ...
Beyond Air® To Participate in Three Upcoming Investor Conferences
GARDEN CITY, N.Y., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of...
Beyond Air® Affiliate Beyond Cancer™ Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentratio...
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nit...
Beyond Air® Schedules First Fiscal Quarter 2023 Financial Results Conference Call and Webcast
Call scheduled for Thursday, August 11th at 4:30 pm Eastern Time Call scheduled for Thursday, August 11th at 4:30 pm Eastern Time
Beyond Air (XAIR) Stock Gains Almost 20% on FDA Approval
XAIR stock is jumping nearly 20% and is trending on many social media websites. The company's LungFit PH device was approved by the FDA.
Beyond Air Scores First FDA Approval For LungFit PH In Respiratory Failure
The FDA has approved Beyond Air Inc's (NASDAQ: XAIR) LungFit PH to treat term and near-term neonates with hypoxic respiratory failure (often referred to as persistent pulmonary hypertension of the newbo...
Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022
LungFit® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun
Beyond Air's LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure
First and only nitric oxide generator and delivery system indicated for the treatment of term and near-term neonates with hypoxic respiratory failure that uses ambient air to provide unlimited, on-dema...
Beyond Air® Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th
GARDEN CITY, New York, June 14, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) fo...
Beyond Cancer™ Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer
Dr. Monson is a board-certified radiation oncologist and brings over 25 years of clinical oncology experience to Beyond Cancer.
Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer
Ms. Jones brings over 30 years of life science based financial experience to Beyond Cancer Ms. Jones brings over 30 years of life science based financial experience to Beyond Cancer
Beyond Air® Schedules Fiscal Year 2022 Financial Results Conference Call and Webcast
Call scheduled for Thursday, June 16th at 4:30 pm Eastern Time Call scheduled for Thursday, June 16th at 4:30 pm Eastern Time
Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at th...
GARDEN CITY, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for t...
Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022
Inhaled NO treatment in patients hospitalized with COVID-19 and other community-acquired viral pneumonia was well tolerated overall, and safe, with improved efficacy parameters as compared to standard s...
Beyond Air® to Participate in Three Upcoming Medical Conferences
GARDEN CITY, N.Y., April 18, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for t...
Beyond Cancer™ Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ul...
Data suggests ultra-high concentration gaseous NO (gNO) induced both innate and adaptive immune cell populations, and a decline in immune suppressor cells, which are indicative of an anti-tumor immune r...
Beyond Cancer™ to Present Two Abstracts for Ultra-High Concentration Nitric Oxide Therapy at the 2022 AACR Annual Mee...
Abstracts for the American Association for Cancer Research (AACR) Annual Meeting were released publicly today at 4:30 PM ET Abstracts for the American Association for Cancer Research (AACR) Annual Meeti...
Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2022
LungFit® PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial launch anticipated in the first half of calendar year 2022 along with European CE Mark
Beyond Air® Announces Participation at Upcoming Investor Conferences in March 2022
GARDEN CITY, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for th...
Beyond Air® Announces Two Appointments to Beyond Cancer™ Board of Directors
Mr. David Dvorak, previously the President and CEO of Zimmer Biomet, brings a 25+ year proven track record of executive leadership, operating experience, and board memberships
New Strong Sell Stocks for January 27th
ARAY, XAIR, and EMKR have been added to the Zacks Rank #5 (Strong Sell) List on January 27, 2022
Beyond Air® Schedules Third Fiscal Quarter 2022 Financial Results Conference Call and Webcast
Call scheduled for Thursday, February 10th at 4:30 pm Eastern Time Call scheduled for Thursday, February 10th at 4:30 pm Eastern Time
Implied Volatility Surging for Beyond Air (XAIR) Stock Options
Investors need to pay close attention to Beyond Air (XAIR) stock based on the movements in the options market lately.
Beyond Air Shares Fall As US Launch Of LungFit PH Not Expected In 2021
Beyond Air Inc (NASDAQ: XAIR) expects a delay in FDA approval for LungFit PH for persistent pulmonary hypertension of the newborn. Based on ongoing communications with the FDA, the company no longer bel...
Why Beyond Air Stock Is Tanking Today
A regulatory delay is weighing heavily on the medical device company's shares today.